Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir
Toxicological Sciences · 01.12.2024 · 202 (2) · 278-290
DOI: 10.1093/toxsci/kfae112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicological Sciences, online erschienen am 20.09.2024. Verfasst von Patricia A Escobar und 11 weiteren Autor:innen. Beteiligte Einrichtung: Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, Merck & Co. Inc., Rahway, NJ 07065, United…. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinogenicity Tests, Cytidine, Mutagenicity Tests. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..
Abstract (Originalsprache)
Molnupiravir is registered or authorized in several countries as a 5-d oral coronavirus disease 2019 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-TP) form. NHC-TP incorporates into severe acute respiratory syndrome coronavirus 2 RNA by the viral RNA-dependent RNA polymerase, resulting in an accumulation of errors in the viral genome, leading to inhibition of viral replication and loss of infectivity. The potential of molnupiravir to induce genomic mutations and DNA damage was comprehensively assessed in several in vitro and in vivo genotoxicity assays and a carcinogenicity study, in accordance with international guideline recommendations and expert opinion. Molnupiravir and NHC induced mutations in vitro in bacteria and mammalian cells but did not induce chromosome damage in in vitro or in vivo assays. The in vivo mutagenic and carcinogenic potential of molnupiravir was tested in a series of in vivo mutagenicity studies in somatic and germ cells (Pig-a Assay and Big Blue® TGR Mutation Assay) and in a carcinogenicity study (transgenic rasH2-Tg mouse), using durations of exposure and doses exceeding those used in clinical therapy. In vitro genotoxicity results are superseded by robustly conducted in vivo studies. Molnupiravir did not increase mutations in somatic or germ cells in the in vivo animal studies and was negative in the carcinogenicity study. The interpretation criteria for each study followed established regulatory guidelines. Taken together, these data indicate that molnupiravir use does not present a genotoxicity or carcinogenicity risk for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nonclinical Drug Safety and Pharmacokinetics Dynamics Metabolism and Bioanalysis, Preclinical Development, Merck & Co. Inc., Rahway, NJ 07065, United States.
ORCID-Profile: Patricia A Escobar, Angela Stermer
Förderung
- Merck Sharp & Dohme LLC
- Merck & Co., Inc.
Zitieren
APA
Escobar, P. A., Sobol, Z., Miller, R. R., Ferry-Martin, S., Stermer, A., Jacob, B., Muniappa, N., Sanchez, R. I., Blanchard, K. T., Galijatovic-Idrizbegovic, A., Amin, R. P., & Troth, S. P. (2024). Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir. Toxicological Sciences, 202(2), 278-290. https://doi.org/10.1093/toxsci/kfae112
Vancouver
Escobar PA, Sobol Z, Miller RR, Ferry-Martin S, Stermer A, Jacob B, et al. Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir. Toxicological Sciences. 2024;202(2):278-290. doi:10.1093/toxsci/kfae112
BibTeX
@article{Escobar2024,
author = {Escobar, Patricia A and Sobol, Zhanna and Miller, Randy R and Ferry-Martin, Sandrine and Stermer, Angela and Jacob, Binod and Muniappa, Nagaraja and Sanchez, Rosa I and Blanchard, Kerry T and Galijatovic-Idrizbegovic, Alema and Amin, Rupesh P and Troth, Sean P},
title = {Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir},
journal = {Toxicological Sciences},
year = {2024},
volume = {202},
number = {2},
pages = {278--290},
doi = {10.1093/toxsci/kfae112}
}
EUVIMED